Description
DE-OBLIGATE FUNDS
Base award description: CHLORHEXIDINE GABAPENTIN LOPERAMIDE
Modification chain · 2 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2021-08-10+$26,529= $26,529
- Mod P000022022-05-27-$11,450= $15,079
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2021-08-10 | +$26,529 | $26,529 | CHLORHEXIDINE GABAPENTIN LOPERAMIDE |
| Mod P00002· FUNDING ONLY ACTION | 2022-05-27 | −$11,450 | $15,079 | DE-OBLIGATE FUNDS |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI DQAQYBV4FLQ3)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C77022P0286 | NATIONAL CMOP OFFICE (36C770) · 6515 · MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES | $95,079 | FY2022 |
| 36C77021P0552 | NATIONAL CMOP OFFICE (36C770) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2021 |
| 36C77021P0419 | NATIONAL CMOP OFFICE (36C770) · 6505 · DRUGS AND BIOLOGICALS | $13,101 | FY2021 |
| 36C77021P0394 | NATIONAL CMOP OFFICE (36C770) · 6505 · DRUGS AND BIOLOGICALS | $49,905 | FY2021 |
| 36C77021P0158 | NATIONAL CMOP OFFICE (36C770) · 6505 · DRUGS AND BIOLOGICALS | $63,788 | FY2021 |
| 36C77021P0122 | NATIONAL CMOP OFFICE (36C770) · 6505 · DRUGS AND BIOLOGICALS | $322,840 | FY2021 |
Other recipients under 6505 from 261-NETWORK CONTRACT OFFICE 21 (36C261) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C26126P1178 | OPTUM FRONTIER THERAPIES II, LLC | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $58,374 | FY2026 |
| 36C26126P1102 | ENVIGO RMS LLC | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $74,586 | FY2026 |
| 36C26126P0961 | 10X GENOMICS, INC. | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $34,600 | FY2026 |
| 36C26126P0997 | SIERRA RADIOPHARMACY LLC | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $247,204 | FY2026 |
| 36C26126P1008 | OPTUM FRONTIER THERAPIES II, LLC | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $58,374 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C26121P1435_3600_-NONE-_-NONE- · retrieved 2026-09-26.